Literature DB >> 33651657

Identification of chondroitin polymerizing factor (CHPF) as tumor promotor in cholangiocarcinoma through regulating cell proliferation, cell apoptosis and cell migration.

Xiaohui Duan1,2,3, Jianhui Yang1,2,3, Bo Jiang1,2,3, Wenbin Duan1,2,3, Rongguang Wei1,2,3, Hui Zhang1,2,3, Xianhai Mao1,2,3,4.   

Abstract

Cholangiocarcinoma (CCA) is a variety of biliary epithelial tumors involving intrahepatic, perihilar and distal bile duct. It is the most common malignant bile duct tumor in the liver and the second most common primary liver cancer, whose molecular mechanism not fully understood. Specifically, the relationship between CCA and chondroitin polymerizing factor (CHPF) is still not clear. In this study, detection of clinical specimens was performed to preliminarily study the role of CHPF in CCA. CCA cells with CHPF knockdown were constructed for in vitro study, which was also used in the construction of mice xenograft model for investigating the role of CHPF in the development of CCA. The results demonstrated that CHPF was significantly upregulated in CCA tissues compared with normal tissues. High expression of CHPF was correlated with more advanced tumor grade. Moreover, knockdown of CHPF significantly inhibited cell proliferation, cell migration, promoted cell apoptosis and arrest cell cycle in G2 phase in vitro, as well as suppressed tumor growth in vivo. In conclusion, CHPF was identified as a tumor promotor in the development and metastasis of CCA, which may provide a novel therapeutic target for the targeted therapy against CCA.

Entities:  

Keywords:  CHPF; Cholangiocarcinoma; cell apoptosis; cell migration; cell proliferation

Mesh:

Substances:

Year:  2021        PMID: 33651657      PMCID: PMC8018512          DOI: 10.1080/15384101.2021.1890951

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  38 in total

1.  Chondroitin sulfate-mediated N-cadherin/β-catenin signaling is associated with basal-like breast cancer cell invasion.

Authors:  Satomi Nadanaka; Hiroki Kinouchi; Hiroshi Kitagawa
Journal:  J Biol Chem       Date:  2017-11-28       Impact factor: 5.157

Review 2.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

Review 3.  Chondroitin Sulfate and Glucosamine as Disease Modifying Anti- Osteoarthritis Dru gs (DMOADs).

Authors:  Veronica Mantovani; Francesca Maccari; Nicola Volpi
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

4.  Molecular cloning of a chondroitin polymerizing factor that cooperates with chondroitin synthase for chondroitin polymerization.

Authors:  Hiroshi Kitagawa; Tomomi Izumikawa; Toru Uyama; Kazuyuki Sugahara
Journal:  J Biol Chem       Date:  2003-04-25       Impact factor: 5.157

Review 5.  Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma.

Authors:  Nestor F Esnaola; Joshua E Meyer; Andreas Karachristos; Jennifer L Maranki; E Ramsay Camp; Crystal S Denlinger
Journal:  Cancer       Date:  2016-01-22       Impact factor: 6.860

6.  Identification of chondroitin sulfate glucuronyltransferase as chondroitin synthase-3 involved in chondroitin polymerization: chondroitin polymerization is achieved by multiple enzyme complexes consisting of chondroitin synthase family members.

Authors:  Tomomi Izumikawa; Toshiyasu Koike; Shoko Shiozawa; Kazuyuki Sugahara; Jun-ichi Tamura; Hiroshi Kitagawa
Journal:  J Biol Chem       Date:  2008-03-03       Impact factor: 5.157

Review 7.  Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe?

Authors:  Maren Diepenbruck; Gerhard Christofori
Journal:  Curr Opin Cell Biol       Date:  2016-06-29       Impact factor: 8.382

8.  Increased CDKL3 expression predicts poor prognosis and enhances malignant phenotypes in esophageal squamous cell carcinoma.

Authors:  Wenguang Ye; Jian Zhu; Dongjie He; Dequan Yu; Haihua Yang; Wei Wang; Mingxin Zhang; Suna Zhou
Journal:  J Cell Biochem       Date:  2018-11-01       Impact factor: 4.429

9.  Inhibitory effects of brusatol delivered using glycosaminoglycan‑placental chondroitin sulfate A‑modified nanoparticles on the proliferation, migration and invasion of cancer cells.

Authors:  Xin Chen; Tailang Yin; Baozhen Zhang; Beini Sun; Jie Chen; Tianxia Xiao; Baobei Wang; Mengxia Li; Jing Yang; Xiujun Fan
Journal:  Int J Mol Med       Date:  2020-06-03       Impact factor: 4.101

Review 10.  The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges.

Authors:  Chin-Yap Loh; Jian Yi Chai; Ting Fang Tang; Won Fen Wong; Gautam Sethi; Muthu Kumaraswamy Shanmugam; Pei Pei Chong; Chung Yeng Looi
Journal:  Cells       Date:  2019-09-20       Impact factor: 6.600

View more
  2 in total

1.  Chondroitin polymerizing factor predicts a poor prognosis and promotes breast cancer progression via the upstream TGF-β1/SMAD3 and JNK axis activation.

Authors:  Qiang-Feng Pan; Wei-Wei Ouyang; Meng-Qi Zhang; Shuo He; Si-Yun Yang; Jun Zhang
Journal:  J Cell Commun Signal       Date:  2022-08-30       Impact factor: 5.908

2.  Bioinformatics and Experimental Analysis of the Prognostic and Predictive Value of the CHPF Gene on Breast Cancer.

Authors:  Wan-Wan Li; Bin Liu; Shu-Qing Dong; Shi-Qing He; Yu-Ying Liu; Si-Yu Wei; Jing-Yi Mou; Jia-Xin Zhang; Zhao Liu
Journal:  Front Oncol       Date:  2022-03-15       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.